Equities research analysts expect that Integra Lifesciences Holdings Corp (NASDAQ:IART) will report $0.67 earnings per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Integra Lifesciences’ earnings, with the highest EPS estimate coming in at $0.68 and the lowest estimate coming in at $0.67. Integra Lifesciences reported earnings of $0.65 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 3.1%. The firm is expected to announce its next earnings report on Thursday, February 20th.
On average, analysts expect that Integra Lifesciences will report full year earnings of $2.74 per share for the current fiscal year, with EPS estimates ranging from $2.73 to $2.75. For the next year, analysts anticipate that the firm will post earnings of $2.99 per share, with EPS estimates ranging from $2.93 to $3.02. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Integra Lifesciences.
Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings data on Thursday, October 24th. The life sciences company reported $0.68 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.03. Integra Lifesciences had a net margin of 3.99% and a return on equity of 16.83%. The firm had revenue of $379.10 million for the quarter, compared to the consensus estimate of $376.85 million. During the same quarter in the prior year, the company posted $0.59 earnings per share. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year.
In other Integra Lifesciences news, VP Eric Schwartz sold 4,007 shares of the company’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $62.25, for a total value of $249,435.75. Also, major shareholder Richard E. Caruso sold 520,000 shares of the company’s stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $60.97, for a total value of $31,704,400.00. Following the completion of the sale, the insider now owns 134,134 shares in the company, valued at approximately $8,178,149.98. The disclosure for this sale can be found here. 4.50% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. Boston Partners boosted its position in Integra Lifesciences by 1.3% in the 2nd quarter. Boston Partners now owns 13,119 shares of the life sciences company’s stock worth $733,000 after purchasing an additional 171 shares in the last quarter. Municipal Employees Retirement System of Michigan lifted its position in shares of Integra Lifesciences by 1.5% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 13,080 shares of the life sciences company’s stock valued at $731,000 after buying an additional 190 shares in the last quarter. LPL Financial LLC lifted its position in shares of Integra Lifesciences by 4.4% during the 2nd quarter. LPL Financial LLC now owns 5,754 shares of the life sciences company’s stock valued at $319,000 after buying an additional 242 shares in the last quarter. California State Teachers Retirement System lifted its position in shares of Integra Lifesciences by 0.3% during the 3rd quarter. California State Teachers Retirement System now owns 112,941 shares of the life sciences company’s stock valued at $6,784,000 after buying an additional 305 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Integra Lifesciences by 8.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,581 shares of the life sciences company’s stock valued at $275,000 after buying an additional 360 shares in the last quarter. Institutional investors and hedge funds own 80.11% of the company’s stock.
IART opened at $61.26 on Monday. Integra Lifesciences has a 52-week low of $42.14 and a 52-week high of $65.09. The company has a quick ratio of 1.92, a current ratio of 2.92 and a debt-to-equity ratio of 1.07. The company has a market cap of $5.23 billion, a P/E ratio of 25.31, a price-to-earnings-growth ratio of 1.79 and a beta of 1.11. The firm’s 50-day moving average price is $59.31 and its 200-day moving average price is $57.88.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Further Reading: FTSE 100 Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.